title: Why is it hard to terminate failing projects in pharmaceutical R&D?
abstract: 'Quick-kill' strategies in pharmaceutical research and development aim to reduce late-stage attrition by bringing project termination decisions forward, to an earlier point in the process. How can the barriers to implementing such strategies be overcome?
authors: Department of Clinical Pharmacology, Pharmaceutical Research &Early Development (pRED), Roche Innovation Centre, Welwyn AL7 1TW, UK.
authors: Richard W
authors: RW
authors: Peck
authors: Institute of Cellular Medicine, Framlington Place, Newcastle University NE2 4HH, UK.
authors: Dennis W
authors: DW
authors: Lendrem
authors: Phruitful Consulting, Newcastle NE1 7RD, UK.
authors: Iain
authors: I
authors: Grant
authors: Institute of Cellular Medicine, Framlington Place, Newcastle University NE2 4HH, UK.
authors: B Clare
authors: BC
authors: Lendrem
authors: Institute of Cellular Medicine, Framlington Place, Newcastle University NE2 4HH, UK.
authors: John D
authors: JD
authors: Isaacs
mesh_terms: D055808:Drug Discovery; D004345:Drug Industry; D006801:Humans; D012106:Research